Investments opportunities
Alsace abounds with investment opportunities, from promising start-ups to tried-and-true big names. Discover the ventures that are preparing the future of medicine...today in Alsace!
Companies looking for funding
Discover the healthcare start-ups backed by our partner, the SEMIA business incubator:
Contacts :
Biotech / Pharma sector : nathalie.domis@alsace-biovalley.com
Medical technologies sector : marilyne.oswald@alsace-biovalley.com
Tomorrow's business winners, are today's prize winners!
The following companies have all been awarded titles in France's national business-creation competitions.
According to their stage of development, many are looking for financial investors in order to continue growing.
National Competition to Fund Innovative Technology Companies 2011
Organized by the French Ministry of Higher Education and Research
Alsace's winners in the "creation/development" category:
- LIGHT VISION:
Miniaturized seeing-aid device: Daniel Ait-Yahiatene
LIGHT VISION is dedicated to the development and the marketing of optoelectronic systems. LIGHT VISION designs intelligent glasses restoring partial vision to people with visual impairment. By combining retinal imaging display and eye tracking technology, this medical device is intended to project real scene images onto a safe retinal area, independently of the eye movement
Learn more
- VIRONEXX:
Development and marketing of new agents in the prevention and treatment of viral infections: Pr. Thomas Baumert.
VIRONEXX aims to become a key player in the creation of innovative approaches for the prevention and therapy of viral infections. With its initial programs, VIRONEXX will focus on the development of unique and innovative biological compounds for the prevention and treatment of chronic HCV infection – a major cause of liver cirrhosis and liver cancer worldwide. Addressing the limitations of standard of care and novel therapies, VIRONEXX will first focus on the development of monoclonal antibodies targeting essential host entry factors.
Learn more
- DEFYMED
Development of a macro-encapsulation device for pancreatic islets: Séverine Sigrist
DEFYMED mission is to develop and market implantable bio-artificial medical devices for various therapeutic applications including liver, kidney, neurological and
endocrine diseases. The first company product is MAILPAN (MAcro-encapsulation of PANcreatic islets), a bio-artificial pancreas which has the potential to restore the
physiological secretion of insulin in type 1 diabetes patients. DEFYMED is a spin-off of the Strasbourg-based CeeD (Centre européen d’études du Diabète) Research Institute.
Learn more
Alsace's winners in the "emerging business" category :
- EPIGEX
Development of innovative epigenetic tools and biomarkers: Ali Hamiche
EPIGEX proposes innovating tools for the research and development of epigenetic diseases encompassing cancer, inflammation, and auto-immune diseases. The company portfolio includes molecular biology reagents for the screening of therapeutic compounds, a technology for the cartography of protein interaction impaired in epigenetic diseases and a set of new tumor biomarkers.
Learn more - ARTIOS NANOMED
Nanotechonological implant for regenerative nanomedicine: Antony Rutt
Using nanomedical technology, Artios is developping tissular regeneration implants for the market. The project is the outcome of Dr. Nadia Benkirane-Jessel's research at the head of the "Active Biomaterials and Tissular Engineering" (mixed research unit UMR S 977, Inserm/U. Strasbourg). Her development of "intelligent" nanostructured biomaterials to accelerate bone or cartilage regeneration has led to a 2011 patent submitted collaboratively by Inserm and the University of Strasbourg.
National Competition to Fund Innovative Technology Companies 2010
Organized by the French Ministry of Higher Education and Research
Alsace's winners in the "creation/development" category:
- BIONEXT
Molecular analysis and assistance in designing and developping compounds for the pharmaceutical and cosmetic industries: Laurent-Philippe ALBOU
BIONEXT is devoted to the development of high performance bioinformatics and chemo-informatics solutions for the life science industry and the academic research.
The company operates BVS™ (Bionext Virtual Screening), an integrated proprietary platform for the detection of molecular targets and anti-targets as well as their functional characterization in various cellular environments.
Learn more - BIOMICA
Introduction of a new medical histocompatibility system: Siamak BAHRAM
BIOMICA develops novel diagnostic kits for solid organ and bone marrow transplantation. These tests are based on a new type of genetic analysis using the MIC genes system.
Learn more - AXILUM ROBOTICS
Development of medical equipment for transcranial magnetic stimulation: Romuald GINHOUX
AXILUM ROBOTICS is a spin-off company from the medical robotics research group of LSIIT, a joint research unit of the University of Strasbourg, CNRS and INSA Strasbourg. Its mission is to develop and commercialize dedicated robotized solutions to assist health care professionals with medical procedures. The first product of AXILUM ROBOTICS is a robot designed to assist psychiatrists and neurologists for Transcranial Magnetic Stimulation, a noninvasive procedure for the treatment of various neurological and psychiatric disorders.
Learn more - UROLEAD
Development of study models and preclinical research in urologic oncology: Thierry MASSFELDER
UROLEAD is a preclinical CRO offering tumorgraft-based services in the urologic sphere : kidney, prostate, bladder.
UROLEAD provices the pharmaceutical and biopharmaceutical industries with a unique experimental research platform combining both in vivo pharmacological models and in vitro assays, using human urologic tumors xenografted in nude mice. UROLEAD has a large collection of patient-derived urologic tumors representing the heterogeneity of these cancers; this collection is in continuous growth, and various characterizations and validations studies are performed on its preclinical models.
Learn more - ALMETIS BIO
Development of a new class of cytotoxic cancer drugs: Marjorie SIDHOUM
ALMETIS is a biopharmaceutical company dedicated to the discovery and the development of innovative metal-based therapeutics in oncology up to clinical phase.
The core technology is about organometallic drugs that have demonstrated anticancer properties answering to usual drawbacks of chemotherapies (toxicities and resistance) and constituting a new class of anticancer drugs.
Learn more
Alsace's winners in the "emerging business" category:
- T STENT
Development of an innovative T stent for endovascular prostheses: Nabil CHAKFE
T-STENT mission is to develop and manufacture implantable prothesis for endovascular surgery. The first product of the company is an endoprosthesis used for endovascular treatment of atheromatous lesions of aortic arch. This innovative device can be used quickly and reliably with minimally invasive technique compared to the actual treatment procedures.
Learn more - DEFYMED
Development of a macro-encapsulation device for pancreatic islets: Séverine Sigrist
DEFYMED mission is to develop and market implantable bio-artificial medical devices for various therapeutic applications including liver, kidney, neurological and endocrine diseases. The first company product is MAILPAN (MAcro-encapsulation of PANcreatic islets), a bio-artificial pancreas which has the potential to restore the physiological secretion of insulin in type 1 diabetes patients. DEFYMED is a spin-off of the Strasbourg-based CeeD (Centre européen d’études du Diabète) Research Institute.
Learn more
Regional "Start-Est Competition" 2008: Alsace's winning companies in the health/life sciences sector
2 prizes were awarded to the most attractive projects, selected by a jury presided by Francis Muller, President of the Alsace Business Angels association:
- PROTIP
ProTip SAS designs, develops and markets medical prostheses and implants using porous titanium with a special focus on ear, nose and throat applications. The company has unique, world-class expertise in manufacturing complex form factors based on medical grade titanium microspheres. This means it can produce an infinite number of variants in final form, porosity and even composition. The biomaterial thus obtained enables permanent implantation even in a septic environment. ProTip manufactures the prostheses using an innovative procedure patented by the company, which obviates the need for an expensive mold.
Learn more
- CELL PROTHERA
CellProthera is a medical biotech company founded in 2008 in Mulhouse (France). Its activity is currently focused on the development of a revolutionary therapeutic approach allowing the regeneration of myocardial tissue following acute myocardial infarct by injection of a cell graft containing autologous adult stem cells (ASC) sampled directly from the patient. CellProthera is the first company having conducted successful proof of principle study with autologous CD34+ stem cells to repair myocardial tissue after acute myocardial infarct (AMI). The clinical outcome indicated an excellent safety profile associated with outstanding clinical benefits.
Learn more
Are you looking for an investment opportunity?
_
E-newsletter
